152 related articles for article (PubMed ID: 21042216)
1. Apolipoprotein A-I mimetic peptides.
Hovingh GK; Bochem AE; Kastelein JJ
Curr Opin Lipidol; 2010 Dec; 21(6):481-6. PubMed ID: 21042216
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
[TBL] [Abstract][Full Text] [Related]
4. The promise of apolipoprotein A-I mimetics.
Mendez AJ
Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
[TBL] [Abstract][Full Text] [Related]
5. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
6. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Barter PJ; Kastelein JJ
J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
[TBL] [Abstract][Full Text] [Related]
7. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Santos-Gallego CG; Ibanez B; Badimon JJ
Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
[TBL] [Abstract][Full Text] [Related]
8. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action.
Getz GS; Wool GD; Reardon CA
Curr Opin Lipidol; 2009 Jun; 20(3):171-5. PubMed ID: 19373084
[TBL] [Abstract][Full Text] [Related]
9. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
10. HDL and Therapy.
Li K; Xie X; Guo Y
Adv Exp Med Biol; 2022; 1377():171-187. PubMed ID: 35575930
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.
Smith JD
Curr Opin Investig Drugs; 2010 Sep; 11(9):989-96. PubMed ID: 20730693
[TBL] [Abstract][Full Text] [Related]
13. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
Barter PJ; Rye KA
J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
[TBL] [Abstract][Full Text] [Related]
14. Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells.
Zhang Q; Liu L; Zheng XY
Int J Cardiol; 2009 Apr; 133(3):286-92. PubMed ID: 19068270
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.
Sethi AA; Amar M; Shamburek RD; Remaley AT
Curr Opin Investig Drugs; 2007 Mar; 8(3):201-12. PubMed ID: 17408115
[TBL] [Abstract][Full Text] [Related]
16. Apo A-1 mimetic peptides as atheroprotective agents in murine models.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Fogelman AM
Curr Drug Targets; 2008 Mar; 9(3):204-9. PubMed ID: 18336238
[TBL] [Abstract][Full Text] [Related]
17. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.
Van Lenten BJ; Navab M; Anantharamaiah GM; Buga GM; Reddy ST; Fogelman AM
Curr Opin Investig Drugs; 2008 Nov; 9(11):1157-62. PubMed ID: 18951294
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
[TBL] [Abstract][Full Text] [Related]
19. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
Watts GF; Chan DC
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1892-5. PubMed ID: 18946055
[No Abstract] [Full Text] [Related]
20. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Gilham D; Wasiak S; Tsujikawa LM; Halliday C; Norek K; Patel RG; Kulikowski E; Johansson J; Sweeney M; Wong NC; Gordon A; McLure K; Young P
Atherosclerosis; 2016 Apr; 247():48-57. PubMed ID: 26868508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
